WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and...

Related Keywords

United States ,America ,American ,Michaelj Polydefkis ,Isabelle Lousada ,Astrazeneca ,Journal Of The American Medical Association ,Ionis Pharmaceuticals ,Prnewswire Ionis Pharmaceuticals Inc ,Drug Administration ,Nasdaq ,Johns Hopkins University School Of Medicine ,Exchange Commission ,Ionis Pharmaceuticals Inc ,Amyloidosis Research Consortium ,Twitter ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire Diabetic Neuropathy ,American Medical Association ,Johns Hopkins University School ,Ruud Dobber ,Biopharmaceuticals Business Unit ,Latin America ,Orphan Drug Designation ,Serum Vitamin ,Recommended Supplementation ,Prescribing Information ,Nc ,